Tag: PER

Health Care

Frost & Sullivan: Rhenu Bhuller Appointed as First Malaysian Partner in Firm

admin

~ Rhenu Bhuller is one of three women partners in Frost & Sullivan globally

KUALA LUMPUR, Malaysia, March 16, 2015 /PRNewswire/ — Frost & Sullivan today announced the appointment of Rhenu Bhuller as a partner in its organization. Rhenu is the first Malaysian to be made a partner in Frost & Sullivan and is one of the three women partners out of a total of 23 partners.

Rhenu Bhuller, first Malaysian partner in Frost & Sullivan

Rhenu Bhuller, first Malaysian partner in Frost & Sullivan

Photo – http://photos.prnewswire.com/prnh/20150316/181866

“We are happy to have Rhenu come on board as a partner in Frost & Sullivan,” said Aroop Zutshi, Global President and Managing Partner, Frost & Sullivan. “Rhenu has been with the company for 15 years and played an integral part in the growth of our Asia Pacific Healthcare team. We hope her new role will propel the team and the company to new heights.”

Rhenu is currently a Senior Vice President and oversees the healthcare practice for Frost & Sullivan in Asia Pacific. She has more than 20 years of working experience in the healthcare industry and is frequently consulted by both the government and private sectors in terms of guiding initiatives and investments both locally and in emerging markets globally.

“We at Frost & Sullivan are proud of Rhenu’s accomplishments thus far and we wish her great success in her new role moving forward,” said Aroop.

Rhenu was the first employee to join Frost & Sullivan Malaysia in 1999 and has since served in Frost & Sullivan’s Sydney, Kuala Lumpur and Singapore offices throughout her career with the company. She is now based at Frost & Sullivan’s Growth Innovation Center in Iskandar Malaysia.

“I am delighted to be named a partner of the firm. It is an amazing recognition not just for me, but for all those that have supported me in making this possible. The journey with Frost & Sullivan has been inspiring, and am very excited about the visionary growth plans we have for the future,” said Rhenu.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact Us: Start the discussion

Media Contact

Carrie Low
Corporate Communications — Asia Pacific
Phone: +603.6204.5910
Email: carrie.low@frost.com

Photo – http://photos.prnasia.com/prnh/20150316/8521501634

Health Care

AMRI Hires VP of International Sales

admin

ALBANY, New York, March 5, 2015 /PRNewswire/ — AMRI (NASDAQ: AMRI) announced today that Michael Pettersson, fills the newly created position of VP of International Sales, effective immediately. He reports to Christopher Conway, Senior Vice President of Global Sales and Marketing.

In this role, Mr. Pettersson will lead the international sales team in an effort to increase worldwide customer value and maximize market share in targeted market segments. Mr. Pettersson will drive strategy for sales and marketing efforts across AMRI’s full ranges of services and products in Drug Discovery, Small Scale Development, API and Drug Products.

“We are pleased to welcome Michael to AMRI,” said Mr. Conway. “As a sales and marketing professional with experience leading international sales activities across various territories worldwide, we are confident that he brings the international commercial expertise that will enhance AMRI’s ability to improve the customer experience on a global basis.

Mr. Pettersson brings more than 30 years of international and commercial sales experience. Most recently he served as Senior Vice President at Teva API with worldwide sales responsibility. Mr. Pettersson holds an MBA in Marketing and Strategy from the Copenhagen Business School.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports drug product development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

 

ENT Fashion

ClearTV Media Teams up with Emmy Winner Karen Schaler to bring “Travel Therapy” to the ClearVision Airport TV Network and to TVChannels4U.

admin

LOS ANGELES, March 2, 2015 /PRNewswire/ — ClearTV Media (ClearTV), announced today it has signed an agreement with Emmy winner Karen Schaler to bring her award winning travel content to the ClearVision TV Network on screens in airports throughout the U.S. and for the Multi-Channel-Network (MCN) TVChannels4U.

TRAVEL THERAPY® features empowering trips to take based on what you’re going through in life, inspired by Karen’s book, TRAVEL THERAPY: Where Do You Need to Go?, and her website www.traveltherapytrips.com.

A three-time Emmy winner, Karen has more than 15-years of network and major market on-air TV experience. Karen hosted ABC’s national travel show, Travel Now, and has worked as a TV correspondent on CNN and an anchor/reporter at NBC in Boston, FOX in Dallas and ABC in Phoenix.

Having traveled to more than 60 countries Karen is a sought after travel and lifestyle keynote speaker, spokesperson and on-air expert having appeared live on TODAY, Inside Edition, BBC, Fox News Channel, Fox & Friends, ABC News Now, Martha Stewart Living Radio and on countless local TV stations across the country.

“Whether you’re stressed out at work, searching for romance or stuck in a rut, traveling to the right destination can be just the ‘therapy’ you need to re-boot and re-energize,” says Karen Schaler, creator and host of Travel Therapy TV segments. “I’m excited to have Travel Therapy on ClearTV, with its commitment to quality programming in airports and online, to help empower viewers to embark on their own life changing journeys.“

Karen’s TRAVEL THERAPY segments highlight top destinations, resorts, spas, culinary experiences and travel adventures from around the world that include insider travel tips and money saving secrets. Karen has also just launched a TRAVEL THERAPY product line featuring clothing, travel and home accessories.

“We are thrilled to bring Karen’s Travel Therapy in front of our audiences who crave this type of premiere travel related content,” notes Jonna Birgans, VP of Programming, ClearTV. “Karen’s passion for travel parallels her passion for journalism and the end result is breathtaking travel content, that I am proud to bring to our viewers!”

About ClearTV Media

Clear TV Media delivers customized TV stations to dynamic Away-From-Home environments bringing airports, healthcare facilities, retailers, and hotel and resorts a new marketing tool that will target, reach and engage a world on-the-go. Clear TV Media has the power to connect with upscale demographics in ways never before imagined by infusing premium content with social media technology. Clear TV Media recently launched TVChannels4u.com. TVChannels4u drives talent and customized programming in the new age of the always-on-demand, mobile and social world. We create, produce and curate the best in Social TV — providing established and new producers with the tools to make and distribute TV series’ like never before. TVChannels4U entertains and engages viewers with original TV programming from a wide variety of genres — Comedy, Drama, News, Sports, Education and Information. To learn more please visit www.cleartvmedia.com www.tvchannels4u.com or Twitter @TVChannels4u

About Karen Schaler

Three-time Emmy award-winning national travel and lifestyle TV host and correspondent, Karen Schaler, is the creator and host and of the TRAVEL THERAPY® TV segments airing nationally on top ABC, NBC, CBS, FOX and CW stations across the country reaching more than 140 TV markets and 140-million households and on WPIX-TV, the CW Network flagship in New York City.

Contact:

Travel Therapy TV
Karen Schaler, 646-256-2077
Kschaler@traveltherapytrips.com

Or

ClearTV Media
Ronnie Seidel, 818-351-7858
press@cleartvmedia.com

Logo – http://photos.prnasia.com/prnh/20150302/8521501256LOGO

Health Care

AMRI Realigns Global Operations to Enhance Continuous Supply Chain for Customers

admin

— Announces Key Leadership Promotions

ALBANY, N.Y., Feb. 13, 2015 /PRNewswire/ — AMRI (NASDAQ: AMRI) today announced that it has implemented several changes to further optimize global business operations in order to enhance continuity from early development through to commercial supply and accelerate the company’s global growth objectives.

The realigned structure will continue to improve performance and reliability by maximizing the value of AMRI’s various integrated services for customers. Enhancing the link between operations and core business segments, together with the corporate-level support functions, will foster real-time decision making, appropriate resource prioritization and integration necessary to create a more adaptive, efficient and customer-centric global pharmaceutical services company.

Steven R. Hagen, Ph.D., Senior Vice President of Manufacturing and Pharmaceuticals, has assumed oversight of AMRI’s global operations infrastructure ensuring that the manufacturing and development operations execute efficiently, safely and to AMRI’s quality standards. With this change, AMRI has improved line-of-sight of all global operations across all of its service offerings and all of its locations.

George Svokos, Senior Vice President Sales and General Manager-API, has assumed responsibility for a newly created Commercial function as Chief Commercial Officer, which comprises Sales and Marketing, Project Management and Supply Chain under one roof. In addition to leading the Commercial function, Mr. Svokos will continue to spearhead AMRI’s integrated API Manufacturing offering that includes Chemical Development and Large Scale API Manufacturing.

William S. Marth, AMRI’s president and chief executive officer, said, “We are committed to continually improving our business operations, and are confident that streamlining our global operations will further enhance our ability to provide customers with a fluid, continuous supply chain across all of our businesses. In addition, the optimization and globalization of customer relations and project management strengthens our ability to manage the customer interface.”

In tandem with the realignment, AMRI also announced the following senior management promotions:

Milton Boyer was promoted to Senior Vice President of Drug Product Manufacturing, from his former role as VP of Parenterals. Mr. Boyer’s expertise from OsoBio will be applied across all phases of Drug Product, which spans from Pre-Formulation and Formulation Development all the way through to Late Phase and Commercial Parenteral Manufacturing.

Christopher Conway was promoted to Senior Vice President of Global Sales and Marketing, and is responsible for all global sales, marketing and customer operations functions. Mr. Conway, who joined AMRI in 2008, was most recently Vice President of Global Sales and Marketing. Before joining AMRI, Mr. Conway held sales and leadership positions of increasing responsibility at Johnson and Johnson.

To effectively support the growing interface between Chemical Development and API and best align AMRI’s resources to effectively manage and transition customer projects, Rajesh Shenoy, Ph.D., was promoted to Senior Director of Global Chemical Development. Dr. Shenoy has been with AMRI since 1998 in various roles of increasing responsibility. Most recently, Dr. Shenoy was Senior Director of Global Project Management. Dr. Shenoy earned a Ph.D. in Organic Chemistry at the University of Akron and conducted postdoctoral research at Kent State University.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids and cytotoxic compounds. Drug Product Manufacturing supports drug product development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

Health Care

AMRI Hires Chief Information Officer

admin

ALBANY, New York, Feb. 10, 2015 /PRNewswire/ — AMRI (NASDAQ: AMRI) announced today that Jimmy Wang, Ph.D., fills the newly created position of Chief Information Officer, effective immediately. He replaces Carl Neumann, Senior Director, Information Technology, who retires this month.

In this role, Dr. Wang will manage and oversee major technology initiatives at AMRI, as well as the day-to-day Information Technology operations. Among his responsibilities will be to implement scalable and agile information technology solutions that align with AMRI’s growth objectives and global operations.

“We are pleased to welcome Jimmy to the AMRI team,” said William S. Marth, president and chief executive officer, AMRI. “As an award-winning industry professional with a proven track record in delivering complex IT transformations, we look forward to leveraging his strategic direction to create a scalable IT infrastructure that will accommodate growth. We appreciate Carl’s many years of dedication and service with AMRI, and wish him the best in his retirement.”

Dr. Wang brings 25 years of experience managing and deploying technology innovations to various technology, telecommunications and global pharmaceutical companies. Most recently he served as Senior Vice President and Chief Information Officer at OPKO Health Inc., where he established the company’s global IT governance process and transformed IT into a centralized delivery organization. Before OPKO Health, Dr. Wang was Senior Vice President and Chief Information Officer at Vertex Pharmaceuticals Inc., where he played a major role in managing implementation, consolidation, and support of Enterprise Operations Support Systems, as well as led the area of scientific computing to use technology to support the area of Innovation and Research. Before Vertex, Dr. Wang was at Teva Pharmaceuticals-America, where he was Vice President and Chief Information Officer. Dr. Wang received his Ph.D. in Operations Research from Southern Methodist University in 1990.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports drug product development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

ENT Fashion

Leading Asia-based Lawyer Joins GMA, Powering Firm Growth into Project Advisory Services and Public Advocacy Support

admin

LAS VEGAS, Jan. 30, 2015 /PRNewswire/ — Global Market Advisors (GMA), a leading consulting firm to the casino gaming, lodging, and airline industries, announced today that William “Bill” Bryson, one of Asia’s leading gaming and hospitality lawyers has joined GMA and will be based in Taipei, Taiwan.

Mr. Bryson, who is licensed in the United States and has lived in Asia for 26 years, brings 30 years of gaming, hospitality, corporate, finance, and public advocacy experience to GMA. The addition of Mr. Bryson to the GMA team will expand the scope of services that GMA can provide to its clients, particularly with respect to the development of casino projects and regulatory advisory to governments.

Steven Gallaway, Partner at Global Market Advisors stated, “With the addition of Bill to the GMA team, the company can now provide clients with a larger array of services in connection with their future development and other projects, both in Asia and elsewhere. Bill’s experience and expertise in law, project development, finance, real estate, M&A, compliance and public advocacy will provide GMA with the capability to work with our clients in virtually every stage of the development process, as well as providing ongoing post-opening services.”

Mr. Bryson will continue to reside and keep an office in Taiwan, which will also expand GMA’s physical presence in the region.

“Bill’s presence in Taipei will complement our existing presence in Bangkok, Thailand, giving us offices in East Asia and Southeast Asia, two of the most important regions for casino development,” said Andrew Klebanow, a Partner at Global Market Advisors. Mr. Klebanow also noted that GMA has a significant history in advising clients in South Korea, Singapore, Japan, Taiwan, and eastern Russia.

About Global Market Advisors, LLC (GMA)
GMA provides clients with market feasibility studies, primary research, economic impact studies, due diligence, payroll control, operations analysis, business and marketing plan development, and player reward program design for the casino gaming, hospitality, aviation and tourism industries.  GMA maintains active clients in the United States, Europe and greater Asia. Learn more by visiting www.globalmarketadvisors.com.

Contact: Steve Gallaway
+1 (303) 759-5944
sgallaway@globalmarketadvisors.com

Health Care

Gabrielle’s Angel Foundation For Cancer Research Welcomes Jho Low To Its Board Of Directors

admin

NEW YORK, Jan. 30, 2015 /PRNewswire/ — Gabrielle’s Angel Foundation announced today that global investor and philanthropist Jho Low has joined the Foundation’s Board of Directors. Low was honored at Angel Ball 2014 – the Foundation’s annual fundraiser – in recognition of his significant humanitarian and philanthropic contributions in support of cancer research.

“Mr. Low has proven his tremendous commitment to cancer research through his charitable work, and we are honored to have him join our board,” said Co-founder Denise Rich.  “We look forward to working closely with him to fulfill our mission of funding more effective therapies for patients with leukemia, lymphoma and related cancers.”

“Gabrielle’s Angel Foundation is an essential organization in the fight against cancer, a disease that has affected so many of us and our families, including my own,” said Jho Low, Chief Executive Officer of Jynwel Capital Limited and Director of Jynwel Charitable Foundation Limited. “Gabrielle’s Angel Foundation has been a partner of Jynwel Charitable Foundation for the last two years, and I am excited to work even more closely with the team on an ongoing basis to help eradicate this deadly disease.”

Low is a global investor and philanthropist who encourages market access and advances human progress through capital and social investments across a diverse range of projects. He is the co-founder and Chief Executive Officer for Jynwel Capital Limited, an international investment firm based in Hong Kong. Low oversees both the operations and investment strategy for the firm and cultivates lifelong partnerships with significant investors in Asia and the Middle East, such as leading sovereign wealth funds, major international investment companies and large family enterprises.

Low has led and invested in numerous mergers and acquisitions, restructurings and financings, cross-border transactions, leveraged buyouts, and other investment projects of various sizes and complexity across a variety of sectors, including media and entertainment, consumer and retail, energy and resources, real estate and hospitality, precious metals, commodities, and infrastructure.

Low is a director of Jynwel Charitable Foundation Limited (“the Foundation”), a charitable institution committed to funding breakthrough programs that scale and accelerate advancements in public health, environmental & wildlife conservation, and education in every corner of the world. The Foundation provides substantial, long-term grants towards global efforts at cancer and research, environmental & wildlife preservation, and education, building on the multi-generational legacy of the Low family’s philanthropy.

Low has served on the board and as an advisor of a number of listed, private and sovereign wealth funded companies. Low is currently a member of the board of the Viceroy Hotel Group and The Electrum Group, and he is also an alternate director of Lilestone Limited (“Myla”). Additionally, Low is Non-executive Chairman, Asia, for EMI Music Publishing, also serving as a member of its advisory board. Through the Foundation, he is a member of The Anderson Assembly and the Board of Visitors of The University of Texas MD Anderson Cancer Center, and he serves on the Board of Directors of Panthera, the world’s leading wild cat conservation organization. Low maintains an active role with National Geographic as a member of its International Council of Advisors and the Advisory Board of National Geographic’s Pristine Seas project. Additionally, he has been selected as one of the founding Members of the Board of Directors of the new IRIN, the humanitarian news service; and is a member of The Trust, a distinguished society recognizing philanthropic leaders who support Children’s National Health System in Washington, DC.

In 2014, Low received the International Entrepreneur of the Year Award from the Houston Asian Chamber of Commerce for his approach to sustainable investing and disruptive philanthropy.

Low graduated with a Bachelor of Science in Economics from The Wharton School of the University of Pennsylvania.

About Gabrielle’s Angel Foundation for Cancer Research

Gabrielle’s Angel Foundation funds the nation’s best and brightest scientific investigators whose research focuses on finding less toxic treatments for patients with leukemia, lymphoma, and related cancers. Since its inception, Gabrielle’s Angel Foundation has awarded $26 million in grants making it one of the largest non-governmental sources of grant support for blood cancer research in the nation. In 2012, the Foundation opened a sister chapter, Gabrielle’s Angel Foundation UK, which provides support for blood cancer research at Great Britain’s leading institutions. Help us on our quest: @CureCancerNow. For more information, please visit: gabriellesangels.org. 

Health Care

Inova Labs Announces New Senior Vice President of Operations

admin

AUSTIN, Texas, Jan. 22, 2015 /PRNewswire/ — Inova Labs Inc., (“Inova Labs“), a leading manufacturer of innovative oxygen therapy solutions, announces the addition of Dale West as the company’s new Senior Vice President of Operations. Mr. West is responsible for Manufacturing, Supply Chain, Manufacturing Engineering and Facilities.

New to Inova Labs, West is not new to the executive management industry. His operations experience encompasses an extensive 20-year background in medical devices and the Home Healthcare industry. Prior to joining the company, he held a variety of executive and senior leadership positions with Philips Respironics, Dynamics Inc., and Frito-Lay. As the Vice President of Global Operations and Supply Chain for Respironics, Mr. West was responsible for all Manufacturing, Strategic Sourcing, Logistics, Customer Service, Distribution, After Market Support and Accounts Receivable. He was a key member of the management team that led to the successful sale of Respironics to Philips.

“We are pleased to have Dale join our executive team as he brings with him a wealth of knowledge and experience that is directly applicable to our business. He will play a key role in our company and as we execute on our next phase of growth.” — John Rush, CEO

Dale West holds a Bachelor of Science in Administrative and Management Science, and a Bachelor of Science in Economics from Carnegie Mellon University. 

About Inova Labs
Inova Labs Inc. is a medical device company specializing in the development and commercialization of innovative products for patients with respiratory conditions. Product offerings include the FDA-cleared LifeChoice®, LifeChoice Activox™ Pro, Sport and 4L Portable Oxygen Concentrators, and the first fully integrated stationary and portable oxygen system concentrator system the Activox DUO2.
www.InovaLabs.com.

CONTACT: Inova Labs, Inc., 3500 Comsouth Drive, Suite 100, Austin, TX 78744 USA, +1.512.617.1700, www.InovaLabs.com

ENT Fashion

Guggenheim UBS MAP Global Art Initiative Expands with Appointment of Sara Raza as Curator for the Middle East and North Africa

admin

– Unprecedented Project of Residencies, Acquisitions, Exhibitions, and Education Programs Launches Its Third Phase

NEW YORK, Jan. 20, 2015 /PRNewswire/ — Richard Armstrong, Director, Solomon R. Guggenheim Museum and Foundation, today announced that London-based curator, writer, editor, and educator Sara Raza has been selected for the third curatorial residency of the Guggenheim UBS MAP Global Art Initiative. As the future Guggenheim UBS MAP Curator, Middle East and North Africa, Ms. Raza will join June Yap (South and Southeast Asia), Pablo Leon de la Barra (Latin America) and Guggenheim staff in realizing this multiyear program, which supports contemporary art, artists, education, and professional exchange in three of the world’s most diverse and dynamic regions.

Photo – http://photos.prnewswire.com/prnh/20150115/169570

Building on MAP’s legacy, Sara Raza will work closely with the Guggenheim’s curatorial staff for a two year residency to research and acquire recent artworks by artists of Middle Eastern and North African origin that represent the most salient artistic and cultural practices of the region. Artworks chosen by Raza will enter the permanent collection and form the basis of an exhibition that will open at the Solomon R. Guggenheim Museum, New York, in 2016, before traveling to the region. She will also collaborate with education staff, as well as contribute to the project’s website.

Ms. Raza was nominated by a committee of esteemed experts on this region: Sam Bardaouil, independent curator, art historian, performance practitioner, and co-founder of Art Reoriented; Okwui Enwezor, Director, Haus der Kunst, Munich, and Director of the Visual Arts Sector for the 56th Venice Biennale; Reem Fadda, Associate Curator, Middle Eastern Art, Abu Dhabi Project, Solomon R. Guggenheim Foundation; Yael Reinharz, Executive Director, Artis; Nada M. Shabout, Professor and Director, Contemporary Arab and Muslim Cultural Studies Institute, University of North Texas; and Christine Tohme, independent curator and founding director of Ashkal Alwan – The Lebanese Association for Plastic Arts, Beirut.

About Sara Raza
Sara Raza holds a Masters in Art History and Theory (20th Century) from Goldsmiths College, University of London, and is currently a Ph.D. candidate at the Royal College of Art. She is the desk editor for West and Central Asia of ArtAsiaPacific magazine, and Head of Education and Public Programmes and Curator of the upcoming 2015 Public Art Festival, organized by Yarat Contemporary Art Space. Over the past ten years, Ms. Raza has organized numerous exhibitions at institutions including the Maraya Art Centre in Sharjah and Alaan Artspace in Riyadh. Ms. Raza co-curated Rhizoma, an exhibition of Saudi Arabian artists commissioned by Edge of Arabia at the 55th Venice Biennale (2014), along with several other international exhibitions at biennials and festivals. Ms. Raza has also served on several educational advisory boards and was a curator of public programs at Tate Modern (2006–08).

About Guggenheim UBS MAP Global Art Initiative
The Guggenheim UBS MAP Global Art Initiative is a multiyear collaboration that charts contemporary art practice in three geographic regions—South and Southeast Asia, Latin America, and the Middle East and North Africa—and encompasses curatorial residencies, international touring exhibitions, audience-driven education programming, and acquisitions for the Solomon R. Guggenheim Museum’s permanent collection. Launched in April 2012, the MAP initiative has brought more than ninety important artworks in all media into the museum’s collection under the auspices of the Guggenheim UBS MAP Purchase Fund, created new educational models with collaborators Asia Society Hong Kong Centre and NTU Centre for Contemporary Art Singapore, and reached hundreds of thousands of visitors through digital initiatives such as the interactive content aggregator MAP Navigator, the Currents educational archive, and online discussion forums. The initiative builds upon and reflects the Solomon R. Guggenheim Foundation’s distinguished history of internationalism, significantly increases the museum’s holdings of art from these dynamic communities, and makes contemporary art, practice, and education accessible on a global scale.

MAP Website: guggenheim.org/MAP
UBS Website: ubs.com/Guggenheim
Social Media: guggenheim.org/social
#GuggUBSMAP

For publicity images, visit: guggenheim.org/pressimages